Predictors of antihypertensive efficiency of renal denervation. (Literature review)

Authors

  • COCIU Maria IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.22

Keywords:

hypertension, renal denervation, , sympathetic nervous system, predictor, efficiency

Abstract

Hypertension remains the leading cause of preventable cardiovascular disease and the main problem of overall mortality globally and also in Europe. Despite pharmacological advances, the control rates of blood pressure remain low worldwide and are far from being satisfactory in Europe. The renal sympathetic denervation is an innovative method, conceived 10 years ago, that involves the disruption of afferent and efferent renal sympathetic fibers by applying radiofrequency energy, thus reducing sympathetic activity and at the same time decreasing the blood pressure. Therefore, renal denervation expands the therapeutic options as being the first goal of hypertension treatment, which means the effective reduction of blood pressure values by achieving therapeutic targets.

Author Biography

COCIU Maria, IMSP Institutul de Cardiologie, Clinica ,,Hipertensiuni arteriale”

cercetător științific

References

Roland E. S., Mahfoudb F. G. et all., European Society of Hypertension position paper on renal denervation. Journal of Hypertension., 2021; Volume 39 Issue 9 p 1733-174.

Osborn J.W., Tyshynsky R., Vulchanova L., Function of renal nerves in kidney physiology and pathophysiology. Annu Rev Physiol., 2021; 83:429–450.

Mahfoud F., Townsend R.R., Kandzari D.E., Kario K., Schmieder R.E., Tsioufis K., et all., Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol., 2021; 77:2909–2919.

Blood Pressure Lowering Treatment Trialists Collaboration., Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet., 2021; 397:1625–1636.

Azizi M., Sanghvi K., Saxena M., Gosse P., Reilly J.P., Levy T., et all., Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet., 2021; S0140-6736/21.

Kario K., Weber M.A., Bo¨hm M., Townsend R.R., Mahfoud F., Schmieder R.E., et all., Effect of renal denervation in attenuating the stress of morning surge in blood pressure: posthoc analysis from the spyral htn-on med trial. Clin Res Cardiol., 2021; 110:725–731.

Bo¨hm M., Kario K., Kandzari D.E., Mahfoud F., Weber M.A., Schmieder R.E., et all., Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial. Lancet., 2020; 395: 1444–1451.

Schmieder R.E., Kandzari D.E., Wang T.D., Lee Y.H., Lazarus G., Pathak A., Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. Journal of Hypertension., 2021; 39:162–168.

Mahfoud F., Mancia G., Schmieder R., Narkiewicz K,, Ruilope L,, Schlaich M,, et all., Renal denervation in high-risk patients with hypertension. J. Am. Coll. Cardiol., 2020; 75:2879–2888.

Schmieder R.E., Mahfoud F., Azizi M., Pathak A., Dimitriadis K., Kroon A.A., et all., European society of hypertension position paper on renal denervation. J. Hypertens., 2018; 36:2042–2048.

Williams B., Mancia G., Spiering W., Agabiti R. E., Azizi M., Burnier M., et al., ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of cardiology and the european society of hypertension: The task force for the management of arterial hypertension of the european society of cardiology and the european society of hypertension. J. Hypertens., 2018; 36:1953–2041.

Kandzari D.E., Bo¨hm M., Mahfoud F., Townsend R.R., Weber M.A., Pocock S., et al., Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet., 2018; 391:2346–2355.

Gosse P., Cremer A., Pereira H., Bobrie G., Chatellier G., Chamontin B., et al., Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation: the denerhtn study (renal denervation for hypertension). Hypertension., 2017; 69:494–500.

Camelia A., Popescu L., Moldovan A., Abordare din perspectivă cronobiologică a pacientului hipertensiv. Romanian Journal of Internal Medicine., 2015; 49, I, 75-84.

Dharam J., Kumbhani M.D., SYMPLICITY I: Oneand Three-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension SYMPLICITY I. Hypertension., 2013; 57(5):911-7.

Rebrova Yu., Ripp T. M. et all., Possibility of evaluating the effectiveness of renal artery sympathetic denervation in resistant hypertension early after radiofrequency ablation. Ter Arkh., 2019; 88(8):10-13.

Reshetnik A., Gohlisch C., et all., Predictors for success in renal denervation-a single centre retrospective analysis. Sci. Rep., 2018; 19-8(1):15505. doi: 10.1038/s41598-018-33783-3.

Dharam J., Kumbhani M.D., Renal Denervation in Patients With Uncontrolled Hypertension SYMPLICITY HTN-3. J. Am. Coll. Cardiol., 2016; 68:2016-25.

Grassi G., Biffi A., Seravalle G., Trevano F.Q., Dell’Oro R., Corrao G., et al., Sympathetic neural overdrive in the obese and overweight state. Hypertension., 2019; 74:349–58.

Joyner M.J., Barnes J.N., Hart E.C., Wallin B.G., Charkoudian N., Neural control of the circulation: How sex and age differences interact in humans. Compr Physiol., 2015; 5:193–215.

Published

2022-04-08